Neuberger Berman Group LLC Morpho Sys Ag Transaction History

Neuberger Berman Group LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 13, 2019	SELL	$23.24 - $26.76 $218,200 - $251,249	-9,389 Closed	0 $0
Q1 2019 May 13, 2019	SELL	$22.55 - $29.84 $239,278 - $316,632	-10,611 Reduced 53.06%	9,389 $213,000
Q4 2018 Feb 12, 2019	BUY	$21.96 - $31.02 $439,200 - $620,400	20,000 New	20,000 $505,000
Q3 2018 Nov 13, 2018	SELL	$26.64 - $35.66 $799,200 - $1.07 Million	-30,000 Closed	0 $0
Q2 2018 Aug 13, 2018	BUY	$25.15 - $30.6 $754,500 - $918,000	30,000 New	30,000 $910,000

11.3M

320K

1.1M

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Market Cap $2.54B
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

Stay updated on Neuberger Berman Group LLC with notifications on news.